Cardlytics (NASDAQ:CDLX - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.07), Zacks reports. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. Cardlytics updated its Q1 2025 guidance to EPS.
Shares of NASDAQ:CDLX traded down $0.04 during trading on Wednesday, reaching $1.98. 1,820,090 shares of the stock were exchanged, compared to its average volume of 997,723. Cardlytics has a 1-year low of $1.77 and a 1-year high of $20.52. The stock has a fifty day moving average of $3.09 and a two-hundred day moving average of $3.52. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The firm has a market cap of $100.63 million, a price-to-earnings ratio of -0.32 and a beta of 1.62.
In other Cardlytics news, CEO Amit Gupta sold 15,160 shares of Cardlytics stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $3.92, for a total transaction of $59,427.20. Following the completion of the transaction, the chief executive officer now owns 215,494 shares in the company, valued at approximately $844,736.48. The trade was a 6.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alexis Desieno sold 8,854 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $3.67, for a total value of $32,494.18. Following the completion of the sale, the chief financial officer now directly owns 121,976 shares of the company's stock, valued at approximately $447,651.92. This trade represents a 6.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 111,454 shares of company stock valued at $391,864. 4.40% of the stock is owned by company insiders.
Separately, Needham & Company LLC reissued a "hold" rating on shares of Cardlytics in a research note on Friday, January 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $6.92.
View Our Latest Stock Analysis on Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cardlytics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.
While Cardlytics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.